Lundbeck
HLUYYDrugs in Pipeline
48
Phase 3 Programs
32
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
Lu AG13909 Phase 2 Est. Readout
Primary completion for Lu AG13909 trial (NCT05669950) in Congenital Adrenal Hyperplasia
SourceVortioxetine (Lu AA21004)
Major Depressive Disorder
Eptinezumab
Chronic Migraine in Children
Zicronapine
Schizophrenia
Vortioxetine 20 mg/day
Depressive Disorder, Major
Idalopirdine
Alzheimer's Disease
Vortioxetine
Depressive Disorder, Major
Lu AF35700
Schizophrenia
Clobazam Low Dose
Epilepsy
Lu AA21004
Generalized Anxiety Disorder
Vortioxetine 10 mg
Major Depressive Disorder
Venlafaxine extended release
Major Depressive Disorder
MK0928, gaboxadol / Duration of Treatment - 1 year
Insomnia
Idalopirdine 60 mg
Alzheimer's Disease
Azilect®
Parkinson's Disease
Bendamustine at a dose of 100 mg/m2
Indolent Non-Hodgkin's Lymphoma
Agomelatine
Major Depressive Disorder
Escitalopram 10-20 mg
Major Depressive Disorder
Lu AF82422
Multiple System Atrophy
Desmoteplase
Acute Ischemic Stroke
Adjunct brexpiprazole
Major Depression Disorder
ADT
Major Depressive Disorder
Vortioxetine 10-20 mg
Major Depressive Disorder
Sertindole
Schizophrenia
Intravenous Carbamazepine (IV CBZ)
Epilepsy
Brexpiprazole
Schizophrenia
MK0928, gaboxadol
Insomnia
Nalmefene
Alcohol Dependence
Clobazam Medium Dose
Epilepsy
Clobazam
Lennox-Gastaut Syndrome
Vortioxetine 10 mg/day
Depressive Disorder, Major
gaboxadol
Insomnia
rasagiline
Parkinson's Disease
Lu AG09222
Migraine
Escitalopram 20 mg
Major Depressive Disorder
Vortioxetine (IV)
Depressive Disorder, Major
Erythropoietin
Bipolar Disorder
Lu AE58054
Schizophrenia
vortioxetine 10 mg tablet
Attention Deficit Hyperactivity Disorder
Bifeprunox
Bipolar I Disorder
Vortioxetine infusion 25 mg
Major Depressive Disorder
Methylprednisoloneacetate
Knee Joint Osteoarthrosis
MK0928, gaboxadol / Duration of Treatment 3 Weeks
Primary Insomnia
Lu AA24493
Friedreich's Ataxia
Zicronapine open-label lead-in 10 mg daily
Schizophrenia
Venlafaxine XL
Major Depressive Disorder
Lu AG13909
Congenital Adrenal Hyperplasia
Melperone HCl
Parkinson's Disease
Lu AA24530
Major Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Vortioxetine (Lu AA21004) | Phase 3 | Major Depressive Disorder | - | - |
Eptinezumab | Phase 3 | Chronic Migraine in Children | - | - |
Zicronapine | Phase 3 | Schizophrenia | - | - |
Vortioxetine 20 mg/day | Phase 3 | Depressive Disorder, Major | - | - |
Idalopirdine | Phase 3 | Alzheimer's Disease | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
Lu AF35700 | Phase 3 | Schizophrenia | - | - |
Clobazam Low Dose | Phase 3 | Epilepsy | - | - |
Lu AA21004 | Phase 3 | Generalized Anxiety Disorder | - | - |
Vortioxetine 10 mg | Phase 3 | Major Depressive Disorder | - | - |
Venlafaxine extended release | Phase 3 | Major Depressive Disorder | - | - |
MK0928, gaboxadol / Duration of Treatment - 1 year | Phase 3 | Insomnia | - | - |
Idalopirdine 60 mg | Phase 3 | Alzheimer's Disease | - | - |
Azilect® | Phase 3 | Parkinson's Disease | - | - |
Bendamustine at a dose of 100 mg/m2 | Phase 3 | Indolent Non-Hodgkin's Lymphoma | - | - |
Agomelatine | Phase 3 | Major Depressive Disorder | - | - |
Escitalopram 10-20 mg | Phase 3 | Major Depressive Disorder | - | - |
Lu AF82422 | Phase 3 | Multiple System Atrophy | - | - |
Desmoteplase | Phase 3 | Acute Ischemic Stroke | - | - |
Adjunct brexpiprazole | Phase 3 | Major Depression Disorder | - | - |
ADT | Phase 3 | Major Depressive Disorder | - | - |
Vortioxetine 10-20 mg | Phase 3 | Major Depressive Disorder | - | - |
Sertindole | Phase 3 | Schizophrenia | - | - |
Intravenous Carbamazepine (IV CBZ) | Phase 3 | Epilepsy | - | - |
Brexpiprazole | Phase 3 | Schizophrenia | - | - |
MK0928, gaboxadol | Phase 3 | Insomnia | - | - |
Nalmefene | Phase 3 | Alcohol Dependence | - | - |
Clobazam Medium Dose | Phase 3 | Epilepsy | - | - |
Clobazam | Phase 3 | Lennox-Gastaut Syndrome | - | - |
Vortioxetine 10 mg/day | Phase 3 | Depressive Disorder, Major | - | - |
gaboxadol | Phase 3 | Insomnia | - | - |
rasagiline | Phase 3 | Parkinson's Disease | - | - |
Lu AG09222 | Phase 2 | Migraine | - | - |
Escitalopram 20 mg | Phase 2 | Major Depressive Disorder | - | - |
Vortioxetine (IV) | Phase 2 | Depressive Disorder, Major | - | - |
Erythropoietin | Phase 2 | Bipolar Disorder | - | - |
Lu AE58054 | Phase 2 | Schizophrenia | - | - |
vortioxetine 10 mg tablet | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
Bifeprunox | Phase 2 | Bipolar I Disorder | - | - |
Vortioxetine infusion 25 mg | Phase 2 | Major Depressive Disorder | - | - |
Methylprednisoloneacetate | Phase 2 | Knee Joint Osteoarthrosis | - | - |
MK0928, gaboxadol / Duration of Treatment 3 Weeks | Phase 2 | Primary Insomnia | - | - |
Lu AA24493 | Phase 2 | Friedreich's Ataxia | - | - |
Zicronapine open-label lead-in 10 mg daily | Phase 2 | Schizophrenia | - | - |
Venlafaxine XL | Phase 2 | Major Depressive Disorder | - | - |
Lu AG13909 | Phase 2 | Congenital Adrenal Hyperplasia | - | - |
Melperone HCl | Phase 2 | Parkinson's Disease | - | - |
Lu AA24530 | Phase 2 | Major Depressive Disorder | - | - |
epilepsy
1 drug in this indication
endogenous Cushing's syndrome
1 drug in this indication
narcolepsy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Lundbeck's drug pipeline?→
CatalystAlert tracks 48 drug candidates in Lundbeck's (HLUYY) pipeline across Phase 3, Phase 2. Its lead program is Vortioxetine (Lu AA21004) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lundbeck's next FDA catalyst?→
Lundbeck's (HLUYY) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HLUYY biotech catalysts?→
Add HLUYY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lundbeck's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.